Newsletter Tool

Featured Story

Pfizer to nearly halve COVID-19 vaccine production timeline, sterile injectables VP says

By Fraiser Kansteiner

Pfizer aims to cut the time to produce a COVID-19 vaccine batch by nearly 50%, Chaz Calitri, VP of sterile injectables, told USA Today. Take DNA production, for instance—the first step in Pfizer's manufacturing process, which originally took 16 days, but could soon be done in as few as nine or 10, Calitri said.

AHA presses FTC to investigate UnitedHealth lab coverage policy, price hikes for travel nurses

By Robert King

The American Hospital Association reached out to FTC to investigate a new policy from UnitedHealthcare on how to cover diagnostic tests and price hikes from nursing staffing agencies.

Verily links with Janssen for at-home COVID-19 immune system study

By Conor Hale

Verily is teaming up with Johnson & Johnson’s Janssen division to observe the body’s earliest immune responses to a coronavirus infection, with people participating in the research from within their own homes.

4 in 5 Americans ready for COVID-19 shot, but vaccine messages remain key, analysis finds

By Beth Snyder Bulik

A new analysis of search and social data finds that 80% of Americans are likely willing to get vaccinated, according to W2O Group. However, vaccine makers still have their work cut out for them—especially among certain groups of people—and messaging will be critical.

AstraZeneca, Oxford race to update COVID-19 vaccine as study flags weak action against variant

By Angus Liu

It didn’t take long before a morale boost for AstraZeneca’s COVID-19 vaccine was overshadowed by disappointment over its waned protection against a newly emerged coronavirus variant, prompting the British pharma and the University of Oxford to start working on boost shots.

Why investors are taking a hard look at the employer-sponsored insurance market

By Paige Minemyer

It's not a secret that healthcare has been a hot market for investment for quite some time. One emerging area that investors are taking a notable interest in is the employer-sponsored insurance market.

Kaiser Permanente income narrowed to $2.2B last year amid COVID-19 squeeze